Health TrialsbyHealthPanel

Effects of Quercetin on Cardiometabolic Outcomes

ConditionCardiometabolic Syndrome
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Central Lancashire

About this trial

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Healthy

Between 18 & 65 years

BMI < 30

Able to give informed consent

Disqualifiers

Pregnancy

Diabetes or any other metabolic/ uncontrolled hypertensive conditions

Food allergies to quercetin

Habitual consumption of quercetin

Trial design

Design model

Parallel

Treatments tested in this trial

  • Quercetin

    Dietary supplement

    Quercetin tablets 400mg 1 x per day

  • Placebo

    Other intervention

    Placebo control 1 x blinded placebo tablet per day

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Quercetin tablets 400mg 1 x p/dExperimental treatment 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Systolic blood pressure

Systolic blood pressure - measured using a digital blood pressure monitor

Time frame
Baseline
2

Systolic blood pressure

Systolic blood pressure - measured using a digital blood pressure monitor

Time frame
20 days

Secondary outcomes

1

Diastolic blood pressure

Diastolic blood pressure - measured using a digital blood pressure monitor

Time frame
Baseline
2

Diastolic blood pressure

Diastolic blood pressure - measured using a digital blood pressure monitor

Time frame
20 days
3

Percent bodyfat

Participants percentage composition of fat - measured using bio-electrical impedance

Time frame
Baseline
4

Percent bodyfat

Participants percentage composition of fat - measured using bio-electrical impedance

Time frame
20 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Central Lancashire

Lead sponsor

DoNotAge.org

Collaborator

Source ClinicalTrials.gov
Apply now